First Parkinson’s patient treated in BlueRock Phase III trial

BlueRock Therapeutics has treated the first patient in its Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy for Parkinson’s disease, according to the company. The therapy, derived from allogeneic pluripotent stem cells, is designed to replace dopamine-producing neurons lost in the disease. The exPDite-2 trial is a randomized, sham surgery-controlled, double-blind study evaluating […] The post First Parkinson’s patient treated in BlueRock Phase III trial appeared first on Longevity.Technology.